A biochip is a collection of miniaturized test sites (microarrays) arranged on a solid substrate that allow many tests to be performed at the same time to achieve high throughput and speed. A biochip can complete thousands of biological reactions.
Market Dynamics:
Rise in burden of chronic diseases, rise in demand for point-of-care testing, rise in application of proteomics and genomics in cancer research, increasing adoption of personalized medicines, and rise in demand for microfluidics materials are major factors expected to augment the growth of the global lab-on-a-chip and microarrays (biochip) market.
For instance, in October 2022, MicrobioSeq (CD Genomics) announced the launch of the Phage Whole-Genome Sequencing to help discover biomarkers and to develop non-antibiotic treatment methods. CD Genomics uses next-generation sequencing and long-read sequencing technologies to provide virus or phage sequencing services and help in-depth studies of structural genomics and comparative genomics.
Key features of the study:
- The report provides in-depth analysis of the global lab-on-a-chip and microarrays (biochip) market, and provide market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global lab-on-a-chip and microarrays (biochip) market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Merck KgaA, QIAGEN NV, BioMérieux, Illumina Inc., Micronit, PerkinElmer Inc., Thermo Fisher Scientific, Fluidigm Corporation, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Abbott Laboratories, Phalanx Biotech Group, and Danaher Corporation (Cepheid), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global lab-on-a-chip and microarrays (biochip) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lab-on-a-chip and microarrays (biochip) market.
Detailed Segmentation:
- Global Lab-on-a-chip and Microarrays (Biochip) Market, By Type:
- Global Lab-on-a-chip and Microarrays (Biochip) Market, By Product:
- Instruments
- Reagents and Consumables
- Software and Services
- Global Lab-on-a-chip and Microarrays (Biochip) Market, By Application:
- Clinical Diagnostics
- Drug Discovery
- Genomics and Proteomics
- Other Application
- Global Lab-on-a-chip and Microarrays (Biochip) Market, By End User:
- Biotechnology
- Pharmaceutical Companies
- Hospitals and Diagnostics Centers
- Academic and Research Institutes
- Global Lab-on-a-chip and Microarrays (Biochip) Market, By Geography:
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
- Company Profiles:
- Merck KgaA
- QIAGEN NV
- BioMérieux
- Illumina Inc.
- Micronit BV
- PerkinElmer Inc.
- Thermo Fisher Scientific
- Fluidigm Corporation
- Bio-Rad Laboratories Inc.
- Agilent Technologies Inc.
- Abbott Laboratories
- Phalanx Biotech Group
- Danaher Corporation (Cepheid)
